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Background: LDL cholesterol (LDLC) lowering has been revolutionized by PCSK9 inhibitors, Alirocumab (Praluent)
and Evolocumab (Repatha), approved as adjuncts to maximally tolerated cholesterol lowering therapy in
heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia, and/or clinical atherosclerotic
cardiovascular disease (CVD) where LDLC lowering is insufficient.
Methods: We applied FDA and insurance eligibility criteria for PCSK9 inhibitor use in 734 hypercholesterolemic
patients serially referred over 3 years who then received ≥ 2 months maximally tolerated LDLC lowering therapy
with follow up LDLC ≥ 70 mg/dl, and in 50 patients approved by insurance for PCSK9 inhibitors. We documented
the percentage of patients with HeFH and/or CVD who met FDA and insurance criteria for PCSK9 inhibitor
therapy using LDLC goal-based guidelines.
Results: Of 734 patients with LDLC ≥ 70 mg/dl after ≥ 2 months maximally tolerated LDLC lowering therapy,
220 (30 %) had HeFH and/or CVD with LDLC > 100 mg/dl, meeting FDA-insurance criteria for PCSK9 inhibitor
therapy. Another 66 (9 %) patients were statin intolerant, without HeFH or CVD. Of the 50 patients whose PCSK9
inhibitor therapy was approved for insurance coverage, 45 (90 %) had LDLC > 100 mg/dl after ≥ 2 months on
maximally tolerated LDLC lowering therapy. Seventeen of these 50 patients (34 %) had HeFH without CVD
(LDLC on treatment 180 ± 50 mg/dl), 15 (30 %) had CVD without HeFH (LDLC on treatment 124 ± 26 mg/dl),
14 (28 %) had both HeFH and CVD (LDLC on treatment 190 ± 53 mg/dl), and 4 (8 %) had neither HeFH nor CVD
(LCLC 142 ± 11 mg/dl).
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Conclusion: Of 734 patients referred for LDLC reduction, with LDLC ≥ 70 mg/dl after ≥ 2 months on maximally
tolerated therapy, 220 (30 %) had HeFH and/or CVD with LDLC > 100 mg/dl, meeting FDA-insurance criteria for
PCSK9 inhibitor therapy as an adjunct to diet-maximally tolerated cholesterol lowering therapy in HeFH or CVD.
If 30 % of patients with high LDLC and HeFH-CVD are eligible for PCSK9 inhibitors, then specialty pharmaceutical
pricing models (~$14,300/year) will collide with tens of millions of HeFH-CVD patients. We speculate that if there was
a 50 % reduction in CVD, then there would be savings of $245 billion, in the middle of the range of estimated PCSK9
inhibitor costs of $185-342 billion. Whether the health care savings arising from the anticipated reduction of CVD
events by PCSK9 inhibitors justify their extraordinary costs in broad population use remains to be determined.
Keywords: PCSK9 inhibitors, LDL cholesterol (LDLC), Heterozygous familial hypercholesterolemia (HeFH),
Atherosclerotic cardiovascular disease (CVD)Background
Lowering of LDL cholesterol (LDLC) has been revolutionized
by the recent release of the PCSK9 inhibitors, Alirocumab
(Praluent) and Evolocumab (Repatha). PCSK9 inhibitors are
approved for patients with heterozygous familial hypercholes-
terolemia (HeFH), homozygous familial hypercholesterolemia
(HoFH), and for patients with atherosclerotic cardiovascular
disease (CVD) unable to achieve LDLC goals despite
maximal tolerated cholesterol-lowering therapy, including
zero dose tolerance (statin intolerance) [1–3]. Preliminary
results of safety-efficacy controlled clinical trials, although
not powered or designed to definitively assess CVD events,
showed about a 50 % risk reduction in CVD events [1, 2].
If the annual cost of the PCSK9 inhibitors were to
remain at $14,000–14,600, then specialty pharmaceut-
ical pricing models previously reserved for drugs which
benefitted limited patient populations will collide with
prospective treatment cohorts in the tens of millions of
patients at high risk for CVD, when using PCSK9 in-
hibitors as an adjunct to diet-maximally tolerated chol-
esterol lowering therapy in heterozygous (HeFH) or
homozygous (HoFH) familial hypercholesterolemia, or
clinical atherosclerotic cardiovascular disease (CVD).
We have applied FDA approved and commercial insur-
ance eligibility criteria for PCSK9 inhibitor use in 734
patients serially referred to our Cholesterol Diagnosis
and Treatment center and receiving ≥ 2 months max-
imally tolerated LDLC lowering diet-drug therapy with
follow up LDLC ≥ 70 mg/dl, to obtain estimates of the
percentage of patients with HeFH and CVD who meet
FDA and commercial insurance eligibility for PCSK9 in-
hibitor treatment using LDLC goal-based guidelines [4, 5].Methods
The study followed a protocol approved by the Jewish
Hospital Institutional Review Board (JH #12–03).
We assessed 734 hypercholesterolemic patients con-
secutively referred to our Cholesterol Treatment Center
from May 2012 to September 2015, who subsequentlyreceived ≥ 2 months of maximally tolerated diet-drug
LDLC lowering therapy, with last follow up LDLC ≥
70 mg/dl. All patients were instructed to consume a
cholesterol lowering diet by a registered dietitian, and
received maximally tolerated LDLC lowering therapy,
predominantly with statins and a small percentage were
also taking ezetimibe and/or colesevelam.
We assessed 50 patients who were approved for
PCSK9 inhibitor therapy with Evolocumab or Alirocu-
mab coverage by their medical insurance programs by
applying the Simon Broome criteria for HeFH [6] and/or
CVD with LDLC above target (> 100 mg/dl [4]) despite
maximally tolerated LDLC lowering therapy.
After an overnight fast, lipids and lipoprotein choles-
terols were serially measured by LabCorp with direct
measurement of LDLC if triglycerides were > 400 mg/dl.
Heterozygous familial hypercholesterolemia (HeFH) was
defined by LDLC ≥ 190 mg/dl and the presence of tendon
xanthomas and/or by hypercholesterolemic first degree
relatives (Simon Broome criteria [6]). Atherosclerotic
cardiovascular disease (CVD) included medical record-
physician referral documented coronary artery, carotid, aor-
tic, or peripheral vascular atherosclerosis, as well as transient
ischemic attack and ischemic stroke. Patients intolerant to≥
3 statin medications were identified as “statin intolerant.”
Separately, we assessed fasting lipid profiles in 8053
patients at their first visit, consecutively referred to our
center over the last 30 years for diagnosis and treatment
of hypercholesterolemia. The 734 patients in the current
report studied after ≥ 2 months on maximal lipid lower-
ing therapy were a subset of these 8053 patients.Results
Of the 734 patients, 210 (29 %) had HeFH, 180 (25 %)
CVD, and 179 were statin intolerant (24 %), Fig. 1. In
the 180 patients who had CVD, the first CVD event was
at age 55 ± 13, median 55 years. Of the 734 patients, 66
(9 %) were statin intolerant, without HeFH or CVD,
Fig. 1. After ≥ 2 months on maximum tolerated LDLC
Fig. 1 Heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular events (CVD) in 734 patients with LDLC ≥70 mg/dl
after ≥ 2 months maximally tolerated cholesterol-lowering therapy. Two hundred and twenty patients with HeFH and/or CVD (30 % of the
referred cohort) eligible for PCSK9 inhibitor therapy by FDA and commercial insurance guidelines by virtue of LDLC on maximal therapy >100
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was 127 mg/dl, in those with CVD events, 101 mg/dl,
and in statin intolerant patients, 123 mg/dl, Fig. 1.
Two hundred and twenty of the 734 patients (30 %)
were eligible by both FDA and commercial insurance cri-
teria for PCSK9 inhibitor treatment, by virtue of having
HeFH and/or CVD, and also having LDLC > 100 mg/dl on
maximally tolerated lipid lowering therapy, Fig. 1. Of these
220 patients, 161 had taken statins, 6 statins plus coleseve-
lam, 3 colesevelam only, 11 statins plus ezetimibe, and 4
statins plus colesevelam and ezetimibe. Of these 220
patients, 56 (25 %) were unable to take any statins,
being intolerant to ≥ 3 different statins.
Of the 220 patients having HeFH and/or a CVD event
with LDLC > 100 mg/dl on maximal tolerated choles-
terol lowering treatment (Fig. 1), 129 had HeFH alone,
with LDLC on therapy 160 ± 51, median 147 mg/dl, 63
had CVD events alone, with LDLC on therapy 134 ± 29,
median 121 mg/dl, and 28 had both HeFH and CVD,
with LDLC on therapy 178 ± 46, median 174 mg/dl. In
those 91 patients with CVD, the first CVD event oc-
curred at age 54 ± 13, median 56 years.
Fifty patients were approved for PCSK9 inhibitor
therapy (Evolocumab or Alirocumab) coverage by their
medical insurance programs. Forty-five of these 50
patients (90 %) had LDLC > 100 mg/dl after ≥ 2 months
on maximally tolerated LDLC lowering therapy, while in
the other 5 patients, LDLC was 80–100 mg/dl. Seven-
teen of the 50 patients (34 %) had only HeFH but no
CVD, with LDLC on treatment 180 ± 50 mg/dl, median
182 mg/dl. Fifteen of the 50 patients (30 %) had onlyCVD but no HeFH, with LDLC on treatment 124 ±
26 mg/dl, median 131 mg/dl, 14 of the 50 (28 %) had
both HeFH and CVD, with on-treatment LDLC 190 ±
53 mg/dl, median 191 mg/dl, and the other 4 (8 %) pa-
tients had no HeFH nor CVD, with LDLC 129, 141, 141,
156 mg/dl. The patients with CVD had their first CVD
event at age 56 ± 11, median 58 years.
Upon evaluation of initial visit LDLC levels in 8053
patients referred to our center over the last 30 years, 9 %
had LDLC ≥190 mg/dl, 12 % fell between 160 and
190 mg/dl, 20 % between 130 and 160 mg/dl, 28 % between
100 and 130 mg/dl, and 31 % had LDLC < 100 mg/dl,
Tables 1 and 2. Overall, 41 % of our 8053 referred patients
had LDLC ≥ 130 mg/dl at their first referral visit, Tables 1
and 2. If LDLC ≥ 160 mg/dl is used as a cutoff for identifi-
cation of hypercholesterolemic patients deserving treat-
ment, 21 % of our 8053 patients had LDLC ≥ 160, and if
LDLC of 190 is used as a treatment cutoff, 9.1 % were
above this level, Tables 1 and 2.
Discussion
Large numbers of subjects with elevated LDLC fail to
achieve treatment targets [7–9], for multiple reasons
including statin intolerance [10, 11], expense, lack of
insurance coverage, or variations in statin availability
across states in insurance, race, and ethnicity [7]. Be-
yond statin effects, the PCSK9 inhibitors now offer the
promise of optimizing LDLC in a majority of patients
with HeFH, CVD, and statin intolerance [2, 5, 12–15].
The issue of healthcare systems either facilitating or
hindering optimal delivery of hyperlipidemia management
Table 1 The distribution of low density lipoprotein cholesterol (LDLC) in 8053 patients serially referred to the Cincinnati Cholesterol









TG<200 mg/dl 1719 (68 %) 1567 (71 %) 1108 (68 %) 617 (64 %) 446 (61 %) 5457 (68 %)
200≤TG<250 198 ( 8 %) 230 (10 %) 190 (12 %) 126 (13 %) 111 (15 %) 855 (11 %)
250≤TG<300 150 ( 6 %) 132 ( 6 %) 115 ( 7 %) 85 (9 %) 83 (11 %) 565 (7 %)
TG≥300 mg/dl 445 (18 %) 292 (13 %) 215 (13 %) 134 (14 %) 90 (12 %) 1176 (15 %)
Whole Column 2512 2221 1628 962 730 8053 (100 %)
Percent of column (31 %) (28 %) (20 %) (12 %) (9 %) (100 %)
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ment in LDLC lowering by the PCSK9 class of medica-
tions [1, 2, 16] at an annual price of $14,000–14,600 per
patient.
In the current study, of the 734 patients referred to a
Lipid Center for diagnosis and treatment of high LDLC
and/or CVD, with LDLC ≥ 70 mg/dl despite maximally
tolerated cholesterol lowering therapy, 30 % were eligible
by FDA [17] and insurance carrier criteria for PCSK9
inhibitor therapy. Our analysis is focused on those high
risk patients for whom PCSK9 inhibitors are specifically
indicated [1, 2, 17] and restricted by medical insurance
carriers, as an adjunct to diet-maximally tolerated
cholesterol lowering therapy in adults with HeFH, and/
or CVD who require additional lowering of LDLC. As
for the general population, the recent CDC report on
cholesterol treatment in the general population of the
US [3] found that 36.7 % (78 million) adults (> 21 years)
were eligible for cholesterol-lowering medication, but of
this group, only 55 % were actively taking a cholesterol
lowering medication (~90 % a statin drug). If 30 % of
the 78 million hypercholesterolemic adults in the general
US population [3] were, as in our current study, eligible
by FDA [17] and insurance carrier criteria for PCSK9
therapy, this would include 11 % of the adult population
or 23.4 million adults.
The population cost of PCSK9 inhibitor therapy
largely depends on the number of subjects judged to
be at high risk by virtue of HeFH with high LDLC
[18–20], and/or by CVD with LDLC above target goals
[4] despite maximally tolerated therapy. In 1.3 million
adults, Elshazly et al. [18] identified the 97th percentile
of LDLC as 190, 160–190 as the 90th–97th percentile,
and 130–160 mg/dl the 72nd–90th percentile. In our
8053 patients referred for diagnosis and therapy of
hypercholesterolemia, 9 % had LDLC ≥ 190 mg/dl andTable 2 LDLC percentiles in the 8053 patients
LDLC percentiles Mean ± SD 2.5th percentile 5th 1
LDLC (mg/dl) 126 ± 48 49 60 721 % had LDLC ≥160 mg/dl. Hence, up to 21 % of our
hypercholesterolemic referrals had LDLC levels usually as-
sociated with HeFH, making them good candidates for ap-
proval [17] of PCSK9 therapy by commercial insurance
carriers. Toth et al. [20] examined NHANES 2005–
2006 data, and identified 27 % with high LDLC (risk
stratum-specific). In studies from the US general popu-
lation 2009–2010 NHANES survey, Fryar et al. [19]
identified “uncontrolled high LDLC (≥ 130 mg/dl)” in
28 % of adults. Kuklina et al. have estimated that more
than one-quarter of adults aged 40–74 have high LDLC
[21]. If 21–36.7 % [3, 19–21] of the general adult US
population is judged to have high LDLC, as above, then
a high LDLC cohort would range from 45 to 78 million
subjects. Extrapolating from our referral cohort where
30 % of hypercholesterolemic patients had HeFH and/
or CVD with LDLC ≥100 mg/dl despite maximally tol-
erated cholesterol lowering therapy, it is possible that
13 to 23 million patients might be candidates for treat-
ment with PCSK9 inhibitors.
Direct costs of CVD include those related to the diag-
nosis and treatment of the condition, while indirect
costs include lost work productivity, loss of future
productivity, unemployment, or death [22]. In 2010,
CVD related direct medical costs in the United States
were estimated to be $273 billion, and indirect costs
172 billion, $445 billion total [23]. The American Heart
Association estimated that direct and indirect costs of
medical care for CVD approached $450 billion in 2010,
and are projected to rise to over $1 trillion by 2030
[24]. Heidenrich et al. [23] have projected that by 2030,
40.5 % of the US population may have some form of
CVD. From 2010 to 2030, real total direct medical costs
of CVD are projected to triple, from $273 billion to
$818 billion. Real indirect costs (due to lost productiv-
ity) for all CVD are estimated to increase from $1720th 25th 50th 75th 90th 95th 97.5th
2 93 120 153 186 212 234
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61 % [23]. Programs targeted to prevention of CVD
should provide substantial overall cost savings [25, 26].
Given current pricing of $14,000–14,600 per patient
per year, annual PCSK9 inhibitor costs might approxi-
mate $185–$342 billion, reflecting the use of a cur-
rently expensive drug for an endemic disease, CVD, the
leading cause of mortality in the USA [23, 27]. In 2011
the annual costs for CVD and stroke were estimated to
be $320.1 billion [24]. If, speculatively, CVD incidence
could be halved by PCSK9 therapy [1, 2, 16], direct
annual savings would be estimated to be $160 billion,
and indirect annual savings might be $85 billion [23],
altogether $245 billion savings, in the middle of the
range of estimated PCSK9 inhibitor costs of $185–342
billion.
Whether and to what degree PCSK9 inhibitor use will
facilitate overall reductions in the cost to society will de-
pend on how widely they will be used, and the percent-
age reduction of all cause and CVD mortality [28].
Overall costs to society also need to include analysis of
any potential adverse effects arising from PCSK9 inhibi-
tor use. On Alirocumab, injection site reactions, myalgia,
neurocognitive events, and ophthalmologic events were
more common than on placebo [1]. On Evolocumab,
nonspecific adverse events (arthralgia, headache, limb
pain, fatigue, and neurocognitive events) were reported
more frequently than in the placebo group [2]. In a
meta-analysis of 25 randomized controlled trials with
PCSK9s, Zhang et al. [16] “detected largely no significant
difference in major adverse events rates between antibody
administration and control treatment, and no difference
between different dosages of Evolocumab.” Within this
frame of reference, we speculate that costs to society arising
from adverse effects specifically attributed to PCSK9
inhibitors may be minimal.
Changes in lifestyle (diet and exercise), to the extent
that they lower CVD event rates [29–31], may play a
role in the cost-benefit analysis by further reducing CVD
event rates in concert with PCSK9 therapy [28].
When statin medications were introduced, cost of
illness calculations were made [32] with the conclusion
that “When only direct medical care costs were consid-
ered, the incremental cost-effectiveness ratios for lifelong
therapy with atorvastatin calcium, 10 mg/day, were gen-
erally positive, ranging from a few thousand to nearly
$20,000 per year of life saved”. When the societal point
of view was adopted and indirect costs were included,
the total costs were generally negative, representing sub-
stantial cost savings (up to $50,000 per year of life saved)
and increased life expectancy for most groups of individ-
uals. Grover et al. [32] concluded that adding the indir-
ect CVD costs associated with productivity losses at
work and home can result in forecasted cost savings tosociety as a whole such that lipid therapy could poten-
tially save lives and money. Cost effectiveness was also
estimated from the use of Crestor (20 mg/day) in the
JUPITER trial [33], and it was concluded that the
treatment was cost-effective for higher risk patients,
Framingham CVD risk ≥ 10 %. Song et al. [22] re-
ported that prevention or reduction in CVD events
could result in cost-savings for employers.
Strengths of our study include documentation that, of
patients referred to a regional center for therapy of high
LDLC, 30 % had HeFH and/or CVD, and despite max-
imal LDLC lowering therapy, retained LDLC > 100 mg/
dl, meeting both FDA indications [17] and commercial
insurance coverage eligibility. We also evaluated a group
of 50 patients approved for and already receiving insur-
ance coverage for PCSK9 inhibitor therapy, who had
HeFH and/or CVD, whose suboptimal LDLC lowering
despite maximal lipid lowering therapy, emphasizes the
medical necessity of PCSK9 inhibition in high risk pa-
tients. It is also noteworthy that within the 50 approved
patients, there were five with LDLC in the 80–97 mg/dl
range. Limitations include bias towards higher LDLC
and CVD by virtue of referral to a regional Cholesterol
Treatment Center, which would increase the percentage
of hypercholesterolemic patients eligible for insurance
coverage. However, in the US general population, the
CDC has estimated that 36.7 % of adults should be
eligible for cholesterol lowering medications [3], with an
LDLC range similar to our 734 patients referred to us
for diagnosis and treatment of hypercholesterolemia.Conclusions
Although the costs for PCSK9 inhibitors when given to an
estimated 13 to 23 million patients would be extraordinary
($185–342 billion), we speculate that if there was a 50 %
reduction in CVD, then there would be savings of $245
billion, in the middle of the range of estimated PCSK9
inhibitor costs of $185–342 billion. Whether the health
care savings arising from the anticipated reduction of
CVD on the PCSK9 inhibitors justify the broad population
use of these agents remains to be determined.
Abbreviations
CVD: cardiovascular disease; HeFH: heterozygous familial
hypercholesterolemia; LDLC: low density lipoprotein cholesterol.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and Design: CJG, PS, NG, AK, MG. Acquisition of data, editing
data: CJG, PS, NG, MP, AK, MG, PW. Analysis of data: CJG, PS, CJG, NG, PW.
Drafting the manuscript CJG, PS, NG, MP, KL, VJ, AK, MG, PW. Given approval
for final manuscript: CJG, PS, NG, MP, KL VJ, AK, MG, PW. Agree to be
accountable: CJG, PS, NG, MP, KL VJ, AK, MG, PW. All authors read and
approved the final manuscript.
Glueck et al. Lipids in Health and Disease  (2016) 15:55 Page 6 of 6Acknowledgement
Supported in part by the Lipoprotein Research Fund of the Jewish Hospital
of Cincinnati.
Received: 13 November 2015 Accepted: 9 March 2016References
1. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular
events. N Engl J Med. 2015;372:1489–99.
2. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular
events. N Engl J Med. 2015;372:1500–9.
3. Mercado C, DeSimone AK, Odom E, Gillespie C, Ayala C, Loustalot F. Prevalence
of cholesterol treatment eligibility and medication use among adults - united
states, 2005–2012. MMWR Morb Mortal Wkly Rep. 2015;64:1305–11.
4. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB,
et al. Implications of recent clinical trials for the national cholesterol
education program adult treatment panel III guidelines. Circulation. 2004;
110:227–39.
5. Shrank WH, Barlow JF, Brennan TA. New therapies in the treatment of high
cholesterol: an argument to return to goal-based lipid guidelines. JAMA.
2015;314:1443–4.
6. Risk of fatal coronary heart disease in familial hypercholesterolaemia.
Scientific steering committee on behalf of the Simon Broome register
group. BMJ. 1991;303:893–6.
7. Hsia SH, Desnoyers ML, Lee ML. Differences in cholesterol management
among states in relation to health insurance and race/ethnicity across the
United States. J Clin Lipidol. 2013;7:675–82.
8. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-
density lipoprotein cholesterol levels among US adults: impact of the 2001
national cholesterol education program guidelines. Ann Pharmacother.
2008;42:1208–15.
9. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, et al.
Lipid treatment assessment project 2: a multinational survey to evaluate the
proportion of patients achieving low-density lipoprotein cholesterol goals.
Circulation. 2009;120:28–34.
10. Glueck CJ, Budhani SB, Masineni SS, Abuchaibe C, Khan N, Wang P, et al.
Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance.
Curr Med Res Opin. 2011;27:1683–90.
11. Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ.
Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis
Can in most cases be safely resolved by vitamin D supplementation. N Am
J Med Sci. 2015;7:86–93.
12. Robinson JG, Kastelein JJ. PCSK9 inhibitors and cardiovascular events.
N Engl J Med. 2015;373:774.
13. Sabatine MS, Wasserman SM, Stein EA. PCSK9 Inhibitors and cardiovascular
events. N Engl J Med. 2015;373:774–5.
14. Stein EA, Raal FJ. Lipid-lowering drug therapy for CVD prevention: looking
into the future. Curr Cardiol Rep. 2015;17:104.
15. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors–the
clinical benefit of lipid drugs. N Engl J Med. 2015;373:1588–91.
16. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and
efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized,
controlled trials. BMC Med. 2015;13:123.
17. Label: PRALUENT- Alirocumab Injection, Solution." DailyMed. NIH: US
National Library of Medicine, 16 Oct. 2015. Web. 10 Mar. 2016.
18. Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, et al.
Non-high-density lipoprotein cholesterol, guideline targets, and population
percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study
(very large database of lipids). J Am Coll Cardiol. 2013;62:1960–5.
19. Fryar CD, Chen TC, Li X. Prevalence of uncontrolled risk factors for
cardiovascular disease: United States. NCHS Data Brief. 1999;2012:1–8.
20. Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the united
states: the national health and nutrition examination survey 2003–2006.
J Clin Lipidol. 2012;6:325–30.
21. Kuklina EV, Carroll MD, Shaw KM, Hirsch R. Trends in high LDL cholesterol,
cholesterol-lowering medication use, and dietary saturated-fat intake:
United States. NCHS Data Brief. 1976;2013:1–8.22. Song X, Quek RG, Gandra SR, Cappell KA, Fowler R, Cong Z. Productivity loss
and indirect costs associated with cardiovascular events and related clinical
procedures. BMC Health Serv Res. 2015;15:245.
23. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al.
Forecasting the future of cardiovascular disease in the United States: a policy
statement from the American heart association. Circulation. 2011;123:933–44.
24. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff Jr DC, Hayman LL, et al.
Value of primordial and primary prevention for cardiovascular disease: a policy
statement from the American Heart Association. Circulation. 2011;124:967–90.
25. Milani RV, Lavie CJ. Impact of worksite wellness intervention on cardiac risk
factors and one-year health care costs. Am J Cardiol. 2009;104:1389–92.
26. Arena R, Guazzi M, Briggs PD, Cahalin LP, Myers J, Kaminsky LA, et al.
Promoting health and wellness in the workplace: a unique opportunity to
establish primary and extended secondary cardiovascular risk reduction
programs. Mayo Clin Proc. 2013;88:605–17.
27. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al.
Heart disease and stroke statistics–2015 update: a report from the American
Heart Association. Circulation. 2015;131:e29–e322.
28. Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker
NC, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine
protease inhibitors on lipid levels and outcomes in patients with primary
hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37:536–45.
29. Tuttle KR, Shuler LA, Packard DP, Milton JE, Daratha KB, Bibus DM, et al.
Comparison of low-fat versus Mediterranean-style dietary intervention after
first myocardial infarction (from The heart institute of spokane diet
intervention and evaluation trial). Am J Cardiol. 2008;101:1523–30.
30. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N.
Mediterranean diet, traditional risk factors, and the rate of cardiovascular
complications after myocardial infarction: final report of the Lyon diet heart
study. Circulation. 1999;99:779–85.
31. Kelley GA, Kelley KS, Roberts S, Haskell W. Efficacy of aerobic exercise and a
prudent diet for improving selected lipids and lipoproteins in adults: a
meta-analysis of randomized controlled trials. BMC Med. 2011;9:74.
32. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of
indirect costs in primary cardiovascular disease prevention: can we save
lives and money with statins? Arch Intern Med. 2003;163:333–9.
33. Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, et al.
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease
based on findings from the JUPITER trial. J Med Econ. 2010;13:428–37.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
